A transition to volume and value-based US growth for Zydus would ensure lower volatility in revenues compared to earlier periods.

Source: https://www.thehindubusinessline.com/portfolio/stock-fundamental-analysis-india/zydus-lifesciences-why-investors-should-accumulate-this-stock/article66518251.ece

Consensus estimates imply a 10.5 per cent earnings CAGR for Zydus in FY22-24.

Source: https://www.thehindubusinessline.com/portfolio/stock-fundamental-analysis-india/zydus-lifesciences-why-investors-should-accumulate-this-stock/article66518251.ece

Zydus Hospital and Healthcare Research Private Ltd and Apex Heart Institute had moved the Gujarat HC seeking a clarification on the directions.

Source: https://indianexpress.com/article/cities/ahmedabad/gujarat-hc-exempts-zydus-apex-from-removing-glass-facades-for-fire-safety-9074347/